South and Central America Carbapenem-Based Antibiotics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

No. of Pages: 124    |    Report Code: TIPRE00028879    |    Category: Life Sciences

Explore in Your Language
Arabic Chinese French German Italian Korean Spanish Japanese
South and Central America Carbapenem-Based Antibiotics Market
Buy Now

The South and Central America carbapenem-based antibiotics market is expected to reach US$ 360.29 million by 2028 from US$ 281.43 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028. 

The market's growth is attributed to factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process for the development of antibiotics is expected to restrain the market's growth during the forecast years.

Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing. 

In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.

According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.

South and Central America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)South and Central America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)

 

SOUTH AND CENTRAL AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION

By Type

•    Meropenem
•    Imipenem
•    Doripenem
•    Tebipenem
•    Others

By Indication

•    Bacterial Meningitis
•    Acute Pelvic Infections
•    Respiratory Tract Infections
•    Intra-Abdominal Infections
•    Urinary Tract Infections
•    Others

By Distribution Channel

•    Hospital Pharmacies
•    Retail Pharmacies
•    Online Pharmacies

By Country

•    Brazil
•    Argentina
•    Rest of South and Central America

Company Profiles

•    ACS Dobfar S.p.A
•    Gland Pharma Limited
•    Merck & Co., Inc.
•    Savior Lifetec
•    Pfizer Inc.
•    Spero Therapeutics
 

South and Central America Carbapenem-Based Antibiotics Strategic Insights

Strategic insights for the South and Central America Carbapenem-Based Antibiotics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/south-and-central-america-carbapenem-based-antibiotics-market-strategic-framework.webp
Get more information on this report

South and Central America Carbapenem-Based Antibiotics Report Scope

Report Attribute Details
Market size in 2021 US$ 281.43 Million
Market Size by 2028 US$ 360.29 Million
Global CAGR (2021 - 2028) 4.4%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • Meropenem
  • Doripenem
  • Imipenem
  • Tebipenem
By Indication
  • Bacterial Meningitis
  • Acute Pelvic Infections
  • Respiratory Tract Infections
  • Intra-Abdominal Infections
  • Urinary Tract Infections
By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Regions and Countries Covered South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Market leaders and key company profiles
  • ACS Dobfar S.p.A
  • Gland Pharma Limited
  • Merck & Co., Inc.
  • Savior Lifetec
  • Pfizer Inc.
  • Spero Therapeutics
    		•
    Get more information on this report

    South and Central America Carbapenem-Based Antibiotics Regional Insights

    The geographic scope of the South and Central America Carbapenem-Based Antibiotics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/south-and-central-america-carbapenem-based-antibiotics-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - South and Central America Carbapenem-Based Antibiotics Market

    1. ACS Dobfar S.p.A
    2. Gland Pharma Limited
    3. Merck & Co., Inc.
    4. Savior Lifetec
    5. Pfizer Inc.
    6. Spero Therapeutics
    Frequently Asked Questions
    How big is the South and Central America Carbapenem-Based Antibiotics Market?

    The South and Central America Carbapenem-Based Antibiotics Market is valued at US$ 281.43 Million in 2021, it is projected to reach US$ 360.29 Million by 2028.

    What is the CAGR for South and Central America Carbapenem-Based Antibiotics Market by (2021 - 2028)?

    As per our report South and Central America Carbapenem-Based Antibiotics Market, the market size is valued at US$ 281.43 Million in 2021, projecting it to reach US$ 360.29 Million by 2028. This translates to a CAGR of approximately 4.4% during the forecast period.

    What segments are covered in this report?

    The South and Central America Carbapenem-Based Antibiotics Market report typically cover these key segments-

    • Type (Meropenem, Doripenem, Imipenem, Tebipenem)
    • Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections)
    • Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies)

    What is the historic period, base year, and forecast period taken for South and Central America Carbapenem-Based Antibiotics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Carbapenem-Based Antibiotics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
    • Who are the major players in South and Central America Carbapenem-Based Antibiotics Market?

    The South and Central America Carbapenem-Based Antibiotics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • ACS Dobfar S.p.A
  • Gland Pharma Limited
  • Merck & Co., Inc.
  • Savior Lifetec
  • Pfizer Inc.
  • Spero Therapeutics
    • Who should buy this report?

    The South and Central America Carbapenem-Based Antibiotics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the South and Central America Carbapenem-Based Antibiotics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    south-and-central-america-carbapenem-based-antibiotics-market